- Home
- EXTR vs AGIO Comparison
EXTR vs AGIO Comparison
Compare EXTR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXTR
- AGIO
- Stock Information
- Founded
- EXTR 1996
- AGIO 2007
- Country
- EXTR United States
- AGIO United States
- Employees
- EXTR N/A
- AGIO N/A
- Industry
- EXTR Telecommunications Equipment
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- EXTR Telecommunications
- AGIO Health Care
- Exchange
- EXTR Nasdaq
- AGIO Nasdaq
- Market Cap
- EXTR 2.5B
- AGIO 2.4B
- IPO Year
- EXTR 1999
- AGIO 2013
- Fundamental
- Price
- EXTR $17.65
- AGIO $40.51
- Analyst Decision
- EXTR Buy
- AGIO Strong Buy
- Analyst Count
- EXTR 4
- AGIO 4
- Target Price
- EXTR $21.25
- AGIO $59.33
- AVG Volume (30 Days)
- EXTR 1.9M
- AGIO 579.1K
- Earning Date
- EXTR 10-29-2025
- AGIO 10-30-2025
- Dividend Yield
- EXTR N/A
- AGIO N/A
- EPS Growth
- EXTR N/A
- AGIO N/A
- EPS
- EXTR 0.06
- AGIO N/A
- Revenue
- EXTR $1,181,108,000.00
- AGIO $44,791,000.00
- Revenue This Year
- EXTR $12.36
- AGIO $25.57
- Revenue Next Year
- EXTR $7.26
- AGIO $153.24
- P/E Ratio
- EXTR $295.69
- AGIO N/A
- Revenue Growth
- EXTR 14.31
- AGIO 36.26
- 52 Week Low
- EXTR $10.10
- AGIO $23.42
- 52 Week High
- EXTR $22.89
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- EXTR 34.98
- AGIO 46.94
- Support Level
- EXTR $16.54
- AGIO $38.90
- Resistance Level
- EXTR $19.90
- AGIO $44.10
- Average True Range (ATR)
- EXTR 0.88
- AGIO 1.80
- MACD
- EXTR -0.28
- AGIO -0.42
- Stochastic Oscillator
- EXTR 21.72
- AGIO 30.09
About EXTR Extreme Networks Inc.
Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.